Login / Signup

Effectiveness of Favipiravir on Nonsevere, Early-Stage COVID-19 in Japan: A Large Observational Study Using the COVID-19 Registry Japan.

Shinya TsuzukiKayoko HayakawaYohei DoiTomohiro ShinozakiYukari UemuraNobuaki MatsunagaMari TeradaSetsuko SuzukiYusuke AsaiGen YamadaSho SaitoTaro ShibataMasashi KondoKazuo IzumiMasayuki HojoTetsuya MizoueKazuhisa YokotaFukumi Nakamura-UchiyamaFumitake SaitoWataru SugiuraNorio Ohmagari
Published in: Infectious diseases and therapy (2022)
In this large cohort from a COVID-19 registry, favipiravir was not associated with a positive effect on the clinical outcome on patients with nonsevere, early-stage COVID-19, suggesting that it is not an essential drug for COVID-19 treatment.
Keyphrases
  • coronavirus disease
  • sars cov
  • early stage
  • randomized controlled trial
  • emergency department
  • radiation therapy
  • lymph node
  • sentinel lymph node
  • smoking cessation
  • combination therapy
  • neoadjuvant chemotherapy